Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder

Código QR

Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder

Takahiro Tsutsumi,1 Hiroko Sugawara,1,2 Ryoko Ito,1 Mizuho Asano,1 Satoru Shimizu,3 Jun Ishigooka,1 Katsuji Nishimura1 1Department of Psychiatry, 2Support Center for Women Health Care Professionals and Research, 3Department of Research, Medical Research Institute, Tokyo Women’s Medical Un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tsutsumi T, Sugawara H, Ito R, Asano M, Shimizu S, Ishigooka J, Nishimura K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	mirtazapine major depressive disorder predictors oversedation jitteriness/anxiety syndrome Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6a2a6a1d76554c2f9436868d691b9028
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Association between anxious distress in a major depressive episode and bipolarity
por: Sugawara H, et al.
Publicado: (2019)

A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
por: Sugawara H, et al.
Publicado: (2016)

Depressive and Anxiety Symptoms Are Predictors of Seizure Recurrence in Adults With Newly Diagnosed Epilepsy
por: Rui Zhong, et al.
Publicado: (2021)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

Identifying factors associated with the hospital readmission rate among patients with major depressive disorder
por: Sharareh Parami, et al.
Publicado: (2021)

The Combination of Serum BDNF, Cortisol and IFN-Gamma Can Assist the Diagnosis of Major Depressive Disorder
por: Chen S, et al.
Publicado: (2021)

Prevalence of Comorbid Anxiety Disorders and Their Associated Factors in Patients with Bipolar Disorder or Major Depressive Disorder
por: Inoue T, et al.
Publicado: (2020)

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang KD, et al.
Publicado: (2017)

Treatment response in relation to subthreshold bipolarity in patients with major depressive disorder receiving antidepressant monotherapy: a post hoc data analysis (KOMDD study)
por: Park YM, et al.
Publicado: (2016)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
por: Kuga A, et al.
Publicado: (2019)

Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis
por: Lindsay M. Melhuish Beaupre, et al.
Publicado: (2021)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

Childhood Emotional Neglect Is Associated With Low Social Support in Chinese Patients With Major Depressive Disorder
por: Xuemei Qin, et al.
Publicado: (2021)

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang G, et al.
Publicado: (2018)

Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021)

Adaptive Affect: The Nature of Anxiety and Depression
por: Morris DW
Publicado: (2019)

Weighted Gene Coexpression Network Analysis Identifies Specific Modules and Hub Genes Related to Major Depression
por: Zhang G, et al.
Publicado: (2020)

Self-stigma in borderline personality disorder – cross-sectional comparison with schizophrenia spectrum disorder, major depressive disorder, and anxiety disorders
por: Grambal A, et al.
Publicado: (2016)

Lifetime Major Discrimination Experiences Moderate the Impact of Depressive Symptoms on Chronic Conditions among Black Americans
por: Kia Skrine Jeffers, et al.
Publicado: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Face Recognition Brain Functional Connectivity in Patients With Major Depression: A Brain Source Localization Study by ERP
por: Lei Lei, et al.
Publicado: (2021)

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression
por: Zincir S, et al.
Publicado: (2016)

Assessment of the Hospital Anxiety and Depression Scale for cancer patients
por: Villoria,Erica, et al.
Publicado: (2018)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Development and Validation of 3-Month Major Post-Stroke Depression Prediction Nomogram After Acute Ischemic Stroke Onset
por: Li G, et al.
Publicado: (2021)

Effects of Polyphenol Supplementations on Improving Depression, Anxiety, and Quality of Life in Patients With Depression
por: Kelly Lin, et al.
Publicado: (2021)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
por: Fuquan Zhang, et al.
Publicado: (2021)

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha MK, et al.
Publicado: (2017)

A preliminary assessment of a combination of rhodiola and saffron in the management of mild–moderate depression
por: Bangratz M, et al.
Publicado: (2018)

Plasma complement component 4 increases in patients with major depressive disorder
por: Wei J, et al.
Publicado: (2017)

Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder
por: Ran S, et al.
Publicado: (2020)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
por: Sugawara N, et al.
Publicado: (2020)

Depression and anxiety
Publicado: (1996)